IMUC is a speculative biotechnology company that I believe is presenting unprecidented upside potential in 2012, and beyond. Some may question this choice, but when you look at its potential, trial results, capital positioning, and its valuation compared to similar companies then I don't believe there is any other company that comes close to matching its upside potential.

Without ICT-107 only 6% of patients lived 3 years, but with ICT-107 40% are disease free, which is incredible

I believe that IMUC has the potential to return mind boggling gains from its current position. The company's now enrolling patients for its Phase II trial for the treatment of glioblastoma. So far, IMUC's lead candidate ICT-107 is showing much better results compared to standard care alone in treating glioblastoma, a disease with an average life-expectancy of just 14 months. During Phase I, ICT-107 treated patients with glioblastoma, and 100% of the patients exceeded their first year of treatment, 40% were disease free in three years, and the company's expecting 18% of the patients to survive through 2012, which would be 5 years. This data is simply incredible especially considering only 6% of glioblastoma patients had surpassed three years with standard care alone.

ImmunoCellular is a very small company with a valuation of only $70 million. The company is enrolling patients for phase II testing of ICT-107, and so far, in early testing, the results have been incredible. The stock has been gaining momentum over the last few months, but has returned a one month gain of 80% with significantly higher volume. Biotech companies have the ability to appreciate very quickly, and if ImmunoCellular continues to produce results similar to its early testing then it could become a once-in-a-lifetime opportunity.

Maarten schreef:Goed nieuws, eindelijk AMEX listing in zicht, daar wacht ik al bijna een jaar op
Up is where we go!

iDB schreef:@insider

Nu nog interessant om in te stappen ?
Of beter in iets anders ?